SEC Form 4 · accession 0001209191-15-066998
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP, Technical Operations
Period of report
Aug 17, 2015
Accepted (ET)
Aug 19, 2015 · 8:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2015 | M | 3,000 | $8.70 | A | 21,027 | D | |
| Common StockF2 | Aug 17, 2015 | S | 1,000 | $30.1318 | D | 20,027 | D | |
| Common StockF3 | Aug 17, 2015 | S | 500 | $30.2724 | D | 19,527 | D | |
| Common StockF4 | Aug 17, 2015 | S | 500 | $30.598 | D | 19,027 | D | |
| Common StockF5 | Aug 17, 2015 | S | 500 | $30.434 | D | 18,527 | D | |
| Common StockF6 | Aug 17, 2015 | S | 400 | $30.1778 | D | 18,127 | D | |
| Common Stock | Aug 17, 2015 | S | 100 | $31.35 | D | 18,027 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $8.70 | Aug 17, 2015 | M | 3,000 | D | — | May 26, 2023 | Common Stock | 3,000 | 55,836 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.135 to $30.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.46 to $30.675, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7The shares subject to this Option vest in 48 equal monthly installments over 4 years following May 27, 2013.